NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning software, which addresses the key gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines.
We are dedicated to developing scalable software solutions that facilitate effective patient selection for cancer immunotherapy, and identifying optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time frame.
Our growing international team (13 countries and counting!) consists of a diverse mix of data scientists, bioinformaticians, immunologists, cancer researchers, and software developers.
NEC OncoImmunity AS is a subsidiary of the NEC Corporation, and is based in the Oslo Cancer Cluster buildings in Oslo, Norway.

Biotechnology

NEC OncoImmunity AS

Richard Stratford

Saverio Niccolini

Heinz Lubenau

Marius Gheorghe

The Leadership Team at NEC OncoImmunity AS is responsible for setting the strategic direction, overseeing major operational decisions, and ensuring alignment with the company's mission to advance personalized cancer immunotherapy and infectious disease vaccines. This team, comprising key executives such as the Chief Drug Development Officer, CEO & Co-founder, Chief Executive Officer, and Principal Bioinformatician, drives innovation, secures funding, and fosters collaborations to propel the company's AI-driven biotech solutions forward.

Leadership Team

About

Team members

Other teams at NEC OncoImmunity AS

Bioinformatics & Data Science